Testing effectiveness (Phase 2)Ended earlyNCT04905212What this trial is testingTelitacicept for Injection (RC18) in Subjects With IgA NephropathyWho this might be right forIgA Nephropathy RemeGen Co., Ltd. 15
Testing effectiveness (Phase 2)Ended earlyNCT05162066What this trial is testingStudy to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)Who this might be right forComplement 3 GlomerulopathyImmunoglobulin A NephropathyMembranous Nephropathy BioCryst Pharmaceuticals 2
Testing effectiveness (Phase 2)Study completedNCT01738035What this trial is testingThe Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal DiseaseWho this might be right forPrimary IgA Nephropathy Calliditas Therapeutics AB 150
Testing effectiveness (Phase 2)Looking for participantsNCT06466135What this trial is testingStudy of WAL0921 in Patients With Glomerular Kidney DiseasesWho this might be right forDiabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more Walden Biosciences 96
Large-scale testing (Phase 3)Study completedNCT04578834What this trial is testingStudy of Efficacy and Safety of LNP023 in Primary IgA Nephropathy PatientsWho this might be right forIgA Nephropathy Novartis Pharmaceuticals 518
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06830395What this trial is testingStudy of CM313 in Subject With IgA NephropathyWho this might be right forIgA Nephropathy Keymed Biosciences Co.Ltd 106
Not applicableLooking for participantsNCT06676007What this trial is testingA Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA NephropathyWho this might be right forIgA Nephropathy (IgAN)Early Initial Therapy Sichuan Provincial People's Hospital 200
Not applicableLooking for participantsNCT07585981What this trial is testingEarly Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.Who this might be right forIgA Glomerulonephritis Chinese PLA General Hospital 30
Not applicableStudy completedNCT00521508What this trial is testingRole of Regulatory T Cells in Pathogenesis of Primary IgA NephropathyWho this might be right forGlomerulonephritis, IGA Centre Hospitalier Universitaire de Saint Etienne 45
Testing effectiveness (Phase 2)Study completedNCT06670352What this trial is testingPhase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANWho this might be right forIgA Nephropathy (IgAN) Haisco Pharmaceutical Group Co., Ltd. 87
Large-scale testing (Phase 3)Looking for participantsNCT06963827What this trial is testingMezagitamab in Adults With Kidney Condition Called IgA NephropathyWho this might be right forKidney Disease Takeda 347
Large-scale testing (Phase 3)Looking for participantsNCT06994845What this trial is testingStudy to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANWho this might be right forPrimary Immunoglobulin A Nephropathy (IgAN) Novartis Pharmaceuticals 31
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06635772What this trial is testingThe Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA NephropathyWho this might be right forImmunoglobulin a Nephropathy Hansoh BioMedical R&D Company 90
Not applicableLooking for participantsNCT06065852What this trial is testingNational Registry of Rare Kidney DiseasesWho this might be right forAdenine Phosphoribosyltransferase DeficiencyAH AmyloidosisAHL Amyloidosis+81 more UK Kidney Association 35,000
Not applicableLooking for participantsNCT06926244What this trial is testingRESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)Who this might be right forIgA Nephropathy (IgAN) Assistance Publique - Hôpitaux de Paris 800
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07606352What this trial is testingSafety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) NephropathyWho this might be right forIgAN Sitala Bio LTD 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT05732402What this trial is testingAn Open-label Study of Povetacicept in Autoantibody-Associated Glomerular DiseasesWho this might be right forLupus NephritisImmunoglobulin A NephropathyMembranous Nephropathy+1 more Alpine Immune Sciences, Inc. 72
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07553494What this trial is testingSLN12140 in Adult Participants With IgA Nephropathy in ChinaWho this might be right forIgA Nephropathy (IgAN) Linno Pharmaceuticals, Inc. 48
Testing effectiveness (Phase 2)Study completedNCT04014335What this trial is testingEvaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA NephropathyWho this might be right forPrimary IgA Nephropathy Ionis Pharmaceuticals, Inc. 23
Post-approval studies (Phase 4)Ended earlyNCT02523768What this trial is testingPrevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive TreatmentWho this might be right forGlomerulonephritisIgAN Centre Hospitalier Universitaire de Saint Etienne 117